Precision Therapeutics. Simplified Disease Management.
MBX Biosciences is pioneering Precision Endocrine Peptide (PEP) therapeutics for patients with endocrine and metabolic disorders. Its pipeline includes MBX 2109 (Phase 2, hypoparathyroidism), MBX 1416 (Phase 1, post-bariatric hypoglycemia), and pre-clinical obesity programs. The company went public on Nasdaq (MBX) in September 2024.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2024
Aug 2024
Jul 2020
Jan 2019
Create a free account to see which investors have funded this company.
Create Free Account
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Outpatient mental health provider offering in-person and virtual therapy, psychiatry, and psychol...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Leading provider of diversified home and community-based health and pharmacy services to medicall...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
